prostate - G2 Intelligence

Genomic Biomarker Tests Endorsed for Early Prostate Cancer Management

by Glenn S. Demby | Jun 15, 2022 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Top of the News-dtet

Revised guidelines from the American Urological Association support limited use of the tests for certain prostate cancer patients.

This content is for Paid Members only.
Register

Already a member? Log in here

New Microchip Could Lead To Home-Based Prostate Cancer Tests

by Toyohashi University of Technology | Mar 7, 2022 | Articles, News, Open Content

Associate professor Kazuhiro Takahashi and Tomoya Maeda (a second-year master’s student) and other members of the Department of Electrical and Electronic Information Engineering at Toyohashi University of Technology have developed a semiconductor sensor capable...

Study Shows Utility of Blood Test for Prostate Cancer Risk Assessment

by Cleveland Diagnostics | Mar 3, 2022 | Articles, News, Open Content

CLEVELAND, OH — Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, recently announced the publication of a large real-world clinical utility study in Urology Practice, a...

Emerging Tests: New Genetic Tests May Be Better than PSA Screening in Assessing Prostate Cancer Risk

by Glenn S. Demby | Nov 16, 2019 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Emerging Tests-dtet, FDA-dtet

...